adalimumab

M2 EQUITYBITES-April 13, 2018-Mylan acquires exclusive license to commercialise biosimilar to Humira

The usual adult dose of Humira for Crohn's disease is: initial dose of 160 mg of adalimumab (recombinant) given subcutaneously (SC) followed by 80 mg SC two weeks after the initial dose, then after four weeks of the initial dose.

The Leverkusen, Germany-based company doesn't ask to halt sales of Humira.

Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to Humira in the US and in various other countries around the world in which AbbVie has intellectual property, excluding Europe.

The 48-week data indicated that the product is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who moved from Humira to Cyltezo at week 24.1.

EA Pharma has been delegated by Eisai to undertake co-promotion on gastrointestinal disease indications for HUMIRA with Abbvie.

Humira sales rose 17% in the first quarter to $1.02 billion.

Summary: A new market study, titled "Discover Global Humira Market Upcoming Trends, Growth Drivers and Challenges" has been featured on WiseGuyReports.

AbbVie may be nearing the limits of how far it can boost Humira's price as cheaper competitors come to market, a problem Allergan is already grappling with as more alternatives to Botox emerge.

"Allergan provides Abbvie a diverse set of assets to help diversify away from Humira, at a very reasonable price," said Maxim Jacobs, North America director of research at Edison Investment Research.